Sanofi, located in Paris, France, manufactures and markets prescription drugs in Europe, the United States and other countries. It focuses on major therapeutic areas such as immunology, neurology, oncology, rare disease, rare blood disorders and diabetes, among others.

In April 2011, Genzyme Corporation became a subsidiary of Sanofi. The deal added products like Cerezyme, Myozyme/Lumizyme and Fabrazyme in its portfolio. Sanofi swapped its Merial Animal Health businesses with Boehringer Ingelheim’s Consumer Healthcare (CHC) business in January 2017. With the acquisition of Chattem in 2010, Sanofi became a major player in the CHC sector. Other smaller acquisitions in the past few years include Ablynx and Bioverativ in 2018, Synthorx and Principia in 2020, Translate Bio and Kadmon in 2021 and Provention Bio in 2023.

Sanofi has collaboration agreements with companies like Regeneron among others. Sanofi has developed and markets Dupixent and Kevzara in collaboration with Regeneron. Initially the companies also co-marketed Praluent and Libtayo. However, from April 2020, the agreement was restructured. Sanofi is now solely responsible for Praluent marketing in outside U.S. markets while Regeneron has the sole responsibility for Praluent in the United States. In 2022, Sanofi also restructured its immuno-oncology collaboration with Regeneron regarding Libtayo by granting them the worldwide exclusive license rights of the drug.

Sanofi’s Biopharma segment comprises three operating segments: Specialty Care (Dupixent, neurology & immunology, rare diseases, rare blood disorders, and oncology), Vaccines and General Medicines (diabetes, cardiovascular, and established products). The company’s Consumer Healthcare (CHC) was established as a standalone business unit in 2019. In October, Sanofi announced it intends to separate the CHC unit through the creation of a publicly-listed entity headquartered in Paris. The separation is not expected to happen before the fourth quarter of 2024.

In 2023, total sales rose 5.4% (at CER) to €43.0 billion. Specialty Care accounted for 41.9% while General Medicines accounted for 28.7% of the company’s total sales. Vaccines accounted for 17.3% of total sales. The CHC unit accounted for 12.1% of 2023 total sales.